Institute of Organic Chemistry, Graz University of Technology, Austria.
Angew Chem Int Ed Engl. 2012 Jul 9;51(28):7035-40. doi: 10.1002/anie.201201955. Epub 2012 Jun 11.
High profile: new activity-based protein profiling (ABPP) probes have been designed that target exclusively monoamine oxidases A and B within living cells (see picture; FAD=flavin adenine dinucleotide, FMN=flavin monodinucleotide). With these probes it could be shown that the MAO inhibitor deprenyl, which is in clinical use against Parkinson's disease, shows unique protein specificity despite its covalent mechanism of action.
新的基于活性的蛋白质分析(ABPP)探针已被设计出来,专门针对活细胞内的单胺氧化酶 A 和 B(见图;FAD=黄素腺嘌呤二核苷酸,FMN=黄素单核苷酸)。使用这些探针可以表明,尽管具有共价作用机制,但临床用于治疗帕金森病的 MAO 抑制剂 deprenyl 具有独特的蛋白质特异性。